logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Krystal Biotech Announced Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Krystal Biotech Today, February 26, 2024, Krystal Biotech ( KRYS ) firm announces its full year financial results and business updates.  Read this press release to learn about the company. New England Journal of Medicine publication of the use of...

Read More

February 26, 2024

0

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Verrica Pharmaceuticals   Verrica Pharmaceuticals ( VRCA ) is a dermatology therapeutics company developing medications for skin diseases.  Today Verrica announced financial results for the fourth quarter and year ended December 31, 2023. Ted White, Verrica Pharmaceuticals' President and Chief...

Read More

February 29, 2024

0

What Happened Over the Past Two Days and Biotech

Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United States’ government decided to ban the importation of Russian oil, liquefied natural gas and coal. This decision was made to further deprive Russia from...

Read More

March 10, 2022

0

Eli Lilly Product Tirzepatide Has Impressive Clinical Trial Results Treating MASH

Eli Lilly in the NEWS Eli Lilly and Company ( LLY ) announced detailed results from the SYNERGY-NASH phase 2 study having 190 patients with or without type 2 diabetes to evaluate the investigational use of tirzepatide in adults with...

Read More

June 10, 2024

0

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Akero Therapeutics Akero Therapeutics ( AKRO ) released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin ( EFX ) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis...

Read More

March 4, 2024

0

Compugen Reports Fourth Quarter and Full Year 2023 Results

Compugen in the NEWS Compugen ( CGEN ) offered its fourth Quarter and full year 2023 results yesterday, which we yearned to learn about for many reasons. These reasons include learning about the outcome of the Company’s  discovered targets and...

Read More

March 6, 2024

0

Today's Bad, Bear Market and Cullinan Oncology Providing 2023 Accomplishments and Financial Results

The Market Today the Stock Market is bearish and most of the biotech stocks are down until the mid-day hour (around 2:30 PM).  Most of the time, the cause of a bearish market has nothing to do with the biotech...

Read More

March 14, 2024

0

Gilead Sciences: The FDA Approved Yescarta® - The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

Gilead Sciences' Product Yescarta Kite - a Gilead Sciences ( GILD ) Company, announced the U.S. FDA has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma ( LBCL ) refractory to first-line chemo-immunotherapy or that which...

Read More

April 4, 2022

0

RegenxBio Announced Completion of a Successful Pre-BLA Meeting with the FDA for RGX-121 for Mucopolysaccharidosis Type II

RegenxBio Today RegenxBio ( RGNX ) announced it completed a successful Pre-Biologics License Application ( BLA ) meeting with the FDA for the RGX-121 treatment of Mucopolysaccharidosis Type II ( MPS II ).  The FDA continues to be aligned with...

Read More

June 18, 2024

0

Altimmune Important Upcoming Presentations

Altimmune Today, June 18, 2024, Altimmune ( ALT ) announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s ( ADA ) 84thScientific Sessions, to...

Read More

June 18, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 156
  • 157
  • 158
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy